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Abstract
Background: As the incidence of hepatocellular carcinoma (HCC) diagnoses in Saudi Arabia has recently increased
due to better diagnostic techniques, the incidence of diagnosed HCC metastasis has also increased. Here, we report
a case of HCC metastasis to the rib with an initially atypical presentation of mastalgia caused by extrahepatic
metastasis.
Case presentation: A 31-year-old woman with a prior hepatitis B viral infection presented with a mass in the left
breast accompanied by mastalgia for a 6-month duration. The patient’s liver enzymes were elevated, and her serum
α-fetoprotein level was particularly high. Computed tomography of her chest and abdomen showed a soft-tissue
mass adhering to the upper chest wall, rib deterioration, and multiple hepatic lesions. A needle biopsy was
immunohistochemically analyzed for Glypican-3, Pan-CK, and CK7 and was confirmed to be metastatic HCC.
Conclusions: This metastatic HCC case is unique because it initially presented as mastalgia. We should consider the
possibility of metastatic disease when assessing patients with unusual presentations who have risk factors for
metastatic carcinoma.
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Background
Hepatocellular carcinoma (HCC) is the 3rd most com-
mon carcinoma worldwide. In Saudi Arabia, it accounts
for approximately 4.8% of all tumors. HCC is the 4th
most common cancer in men and the 8th most common
cancer in women [1] and is defined as an epithelial
tumor that arises from the malignant transformation of
hepatocytes. HCC is the most common primary liver
malignancy and is often discovered in patients who
present with cirrhosis or other chronic liver diseases [2].
Extrahepatic metastasis (Em) of HCC (EmHCC) is usu-
ally seen in a terminal stage and has an aggressive pro-
gression [3]. EmHCC manifests in approximately half of
HCC cases and is most commonly found in the lung,
lymph nodes, or bones [4]. Bone metastasis accounts for
1.6–16% of HCC metastasis. Em occurs most commonly
to the ribs (six reported cases), followed by the man-
dible, the humerus, the femur, the iliac bone, and the
vertebral bodies [5, 6]. The prognosis of Em is poor, with
a 1-year survival rate of approximately 40% [7–9]. In this
report, we present an unusual metastatic HCC case that
initially presented as mastalgia caused by an EmHCC to
the rib cage.
Case presentation
A 31-year-old housewife of African descent with a prior
history of chronic hepatitis B infection and
hypothyroidism presented with a mass in her left breast
and mastalgia lasting for 6 months. Her vital signs were
normal. Upon physical examination, a non-mobile, round
mass of approximately 5 × 6 cm was palpated in the left
breast. The rest of the exam was normal, and assessment
of other clinical parameters showed nothing unusual.
However, laboratory findings showed an elevated serum
α-fetoprotein (AFP) level of 402.5 ng/cc and elevated ala-
nine transaminase and aspartate transaminase levels of 94
and 651 IU/L, respectively (Table 1).
Although diagnostic mammography findings were
negative, a breast examination showed a retrograndu-
lar versus submuscular hypoechoic mass measuring
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5.2 × 4.2 × 5.4 cm in the left breast (Fig. 1). Conse-
quently, the patient received a contrast chest and ab-
domen CT, which showed multifocal hypodense
hepatic lesions with centralized necrosis and a tu-
moral thrombus in the intrahepatic portal vein (Fig. 2).
A large, solitary mass with a large soft-tissue compo-
nent was also seen on one of the patient’s left ribs,
which was accompanied by deterioration of the pa-
tient’s 3rd rib bone. The mass bordered the ipsilateral
pectoralis muscle, and it is likely that there was local-
ized invasion (Fig. 3).
The patient subsequently received an image-guided
needle biopsy of the mass. The biopsy specimen was
subjected to specialized immunohistochemical staining
(Fig. 4). The pathology report confirmed a metastatic
epithelial tumor with morphological features that were
hepatic in origin (Fig. 5).
Discussion
Accurate diagnosis is the 1st step in optimal cancer care.
However, because EmHCC often presents atypically, pa-
tients might be misdiagnosed and not receive appropriate
treatment in a timely manner. Moreover, distinguishing a
primary cancer from secondary metastatic lesions can be
challenging. Fortunately, the evolution of diagnostic im-
aging modalities can assist the physician in accurate diag-
nostic practices.
In our study, a contrast-enhanced CT scan of the chest
showed a destructive lesion on the left 3rd rib as a large
soft-tissue mass that anteriorly invaded the ipsilateral
pectoralis muscle, causing localized invasion of the
breast tissue. Moreover, a contrast-enhanced CT scan of
the abdomen showed multifocal hypodense hepatic le-
sions with centralized necrosis that surrounded an en-
hanced pseudocapsule and distal branches of the portal
vein, all of which are features suggestive of HCC [10].
Nevertheless, a noninvasive approach to diagnose
EmHCC might not be sufficiently precise. Undoubtedly,
immunohistochemical diagnosis from needle aspiration
biopsy is the gold standard because it provides details
about the neoplastic cells involved in the malignant dis-
ease process (e.g., arrangement pattern and stain con-
firmation). Our patient was diagnosed with stage IV
HCC with a metastatic epithelial tumor to the 3rd rib.
Table 1 Biochemical test results and tumor marker levels
Test Result (normal range)
CBC Hemoglobin 11.8 (13.0–18.0) g/dL
WBC count 8.7 (4.0–11.0) k/μL
Platelet 150 (140–450) k/μL
LFT Serum total protein 6.1 (6–8) g/dL
Albumin 2.3 (3.5–5) g/dL
SGOT 651 (15–37) U/L
SGPT 94 (14–63) U/L
LDH 726 (81–234) U/L
GGTP 376 (5–55) U/L
ALP 238 (46–116) U/L
Tumor markers AFP 402.5 (0–40) ng/mL
BHCG 1.20 (5–25) mlU/mL
CA 125 27.7 (<35) U/mL
CA 19-9 605.57 (0–37) U/mL
CEA 0.50 (≤3) ng/mL
Fig. 1 Grayscale and Doppler ultrasound of the left breast exhibit a large (5.2 × 4.2 × 5.4 cm) hypoechoic/anechoic lesion located at the left retro-pectoralis
region with no evidence of vascularity
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This diagnosis was confirmed by specialized immunohis-
tochemical stains including Glypican-3, cytokeratin pan-
antibody (Pan-CK), and cytokeratin 7 (CK7). Glypican-3
is a membrane-bound heparin sulfate proteoglycan that
is expressed only in HCC cells and their metastases
(Fig. 5) [11].
Interestingly, hepatocytes can grow in trabecular
structures that are surrounded by tissue expressing
high levels of ECM proteins such as laminin, vitro-
nectin, collagen, and fibronectin [12]. The defective
cell adhesion and migration and proteolysis of extra-
cellular matrix proteins are necessary steps in meta-
static development [13]. However, EmHCC can be
disseminated either hematogenously or lymphatically
to form new neoplastic foci in sites other than the
original tumor [14].
The clinical course and prognosis of EmHCC are not
entirely clear. However, recently developed management
options can prolong the life expectancy of HCC patients.
Furthermore, systemic therapy with sorafenib combined
with 5-fluorouracil has shown promising effects for
HCC treatment [15].
Conclusions
In summary, although EmHCC diagnosis can be challen-
ging, physicians should be alert to the possibility of en-
countering this disease in their differential diagnoses.
Regardless of AFP levels, EmHCC requires meticulous
evaluation to reach an appropriate diagnosis and to pro-
vide suitable treatment.
Fig. 2 Transaxial images of the contrast-enhanced CT scan of the
abdomen at the portal venous phase shows a multifocal, ill-defined,
and relatively hypodense hepatic lesion that involves the right and left
hepatic lobes and surrounds an enhanced pseudocapsule. There are
multiple subcapsular undulated margins, which are suggestive of
subcapsular retraction. The lesions show mass effects on the
intrahepatic portion of the IVC with significant narrowing and medial
deviation. The indistinct appearance of the middle hepatic vein and
the distal branches of the portal vein suggest that HCC invaded
these areas
Fig. 3 Transaxial images of the contrast-enhanced CT scan of the
chest. Left: mediastinal window. Right: bone window shows an
aggressive, destructive bone lesion with a large soft-tissue component
arising from the 3rd anterolateral rib, which invaded the adjacent
pleural surfaces and the ipsilateral major pectoral muscle
Fig. 4 Higher magnification show the details of the cancer cells,
which are arranged in a trabecular sinusoidal pattern with a clear
cytoplasm and pleomorphic nuclei. Mitoses are seen in some areas,
as are some foci of necrosis
Fig. 5 Bone with hepatocellular metastases; the brown staining is
positive for glypican 3, which is specific for HCC
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